

Minutes of the

5th Annual General Meeting

of the shareholders of

medmix Ltd

held on

Thursday, 16 April 2026, 10.00 a.m.

at

Lorzensaal, Dorfplatz 3, 6330 Cham, Switzerland

The chairman of the Board of Directors of medmix Ltd (the "**Chairman**"), Rob ten Hoedt, formally opens the 5th Annual General Meeting of medmix Ltd at 10.00 a.m. He welcomes the shareholders in German and explains that the meeting will be held in English to reach medmix' stakeholders worldwide. He then continues in English, introduces himself and notes the following:

The invitation to today's Annual General Meeting was published in the Swiss Official Gazette of Commerce on 18 March 2026. This means that the statutory notice period of 20 days has been complied with. The agenda and the proposals were also sent to the shareholders on 18 March 2026.

Pursuant to Art. 699a and Art. 734 of the Swiss Code of Obligations ("**CO**"), the annual report, the compensation report and the auditor's reports must be made available to the shareholders no later than 20 days before the Annual General Meeting. This is the case. The complete annual report, including the compensation report, the sustainability report and the auditor's reports, has been available on medmix' website since 26 February 2026. Furthermore, the résumés of the members of the Board of Directors proposed for re-election are available on medmix' website.

In advance of the Annual General Meeting, no requests for the inclusion of items on the agenda were received from shareholders, nor were there any counterproposals or questions regarding items on the agenda.

The meeting is therefore convened in accordance with the law and the articles of association of medmix Ltd and constitutes a quorum with regard to the published agenda items.

The Chairman explains how shareholders can register, should they wish to speak, and points out that the meeting will be recorded on video.

The Chairman welcomes and introduces the members of the Board of Directors (all of them attending the meeting). He then welcomes and introduces the members of the Executive Committee, in particular the head of strategy and development (new hire) and the new CFO (promoted).

The Chairman then welcomes Simon Niklaus and Mrs. Verena Freud, representing KPMG, as well as Mr. Gian Andri Töndury, representing the independent proxy, Proxy Voting Services GmbH.

The Chairman hands over to Gian Andri Töndury who confirms that he has provided the Board of Directors with general information on the voting instructions received from shareholders no earlier than three working days prior to the Annual General Meeting. This general information included a summary of the yes-votes, no-votes, and abstentions for all agenda items.

The Chairman states that, in accordance with Art. 14 of the articles of association, today's Annual General Meeting is chaired by Rob ten Hoedt as Chairman. Xavier Schops acts as Secretary. The Chairman then welcomes the vote counters, Mr. Christoph Bischofberger (UBS Switzerland) and Daniel Schmidt-Badoux (Commerzbank AG).

The Chairman states that the minutes of last year's Annual General Meeting have been made available on medmix' website within the statutory period.

The Chairman explains that voting will be made electronically. For the vote on the discharge under agenda item 3, the voting devices of those shareholders who are not legally allowed to take part in this vote have been blocked in the system. Tiwel Holding AG also voluntarily accepted this restriction. The functioning of the electronic voting devices is demonstrated in a short video. The Chairman asks the shareholders to participate in a test question to check the functioning of their device.

The Chairman then explains that the Annual General Meeting shall pass resolutions on each of today's agenda items by a majority of the votes represented, in accordance with art. 15 para. 1 of the articles of association.

The Chairman hands over to the Chief Executive Officer.

Speech by René Willi, Chief Executive Officer

René Willi welcomes the shareholders in German and continues in English, stating the following:

“Good morning, dear shareholders and dear colleagues,

In 2025, medmix demonstrated resilience, discipline, and focused execution amid global uncertainty. While the world economy remained stable, growth stayed below the levels seen before. The macroeconomic environment continued to test businesses’ ability to adapt. In addition, inflation dynamics, tariffs and exchange rate movements continued to present challenges, requiring disciplined and carefully calibrated commercial and pricing actions. In this context, our global manufacturing footprint and robust supply-chain capabilities served as key differentiators, enabling us to mitigate many disruptions and exploit new opportunities.

Despite the challenging environment, we remained focused on what we do best: delivering high-precision, reliable, and sustainable solutions for healthcare, industrial, and beauty markets worldwide. Safeguarding profitability amid lower revenues was a key priority throughout the year. The decline in revenue was driven by softer demand in our Beauty business unit and the dual sourcing impact of one customer in the Drug Delivery business unit, which could not be fully compensated by the above-market growth of our Dental business unit and the solid performance delivered by our Industry business unit.

In 2025, we generated revenues of CHF 448.0 million, 4.8% lower than in 2024 on an FX adjusted organic basis and in line with our revised full-year guidance. We made strong progress on profitability: EBIT, EBITDA, and the adjusted EBITDA margin all improved significantly. Adjusted EBITDA margin increased 90 percentage points and exceeded the upper end of our guidance range. This performance was driven by lower operating expenses resulting from our Growth and Efficiency program as well as strong volumes and margins in Dental.

As you can see in one of the highlights-boxes on the slide, medmix has been included in the 2026 edition of the “World’s Best Companies in Sustainable Growth”, a global ranking compiled by TIME in collaboration with data and research firm Statista. Out of more than four thousand companies assessed, the list recognizes 500 companies worldwide that pair strong, profitable development with demonstrable progress in environmental performance, placing medmix among an elite group of organizations that excel across select critical dimensions, such as financial stability and environmental impact, including greenhouse gas emissions, waste management, water consumption, and renewable energy usage.

Also, regarding our overall strategy implementation, we have made significant progress: In Dental, we continued to outpace overall dental industry growth with our existing portfolio and are preparing with customers to launch our next-generation dental applicators. We continue to increase exposure to faster-growing product categories to maintain our leading position in dental applicators. In Surgery, we are now producing a full range of products at our Atlanta site. We have launched significant co-development projects with existing customers and are successfully broadening our customer base. In Drug Delivery we are progressing well with the commercialization of our two product platforms. We have a solid pipeline, which should lead to significant growth in 2028 and beyond. The Industry business unit returned to growth despite sluggish end-markets. Throughout 2025, we focused on improving efficiency and are making solid progress in insourcing third-party manufacturing in the USA to our Atlanta site, enhancing value creation. We have steadily improved profitability through our Growth and Efficiency program, focusing on streamlining product flows and further automating production processes at our Valencia facility.

Looking ahead, the economic landscape remains challenging, with continued geopolitical uncertainty and structural shifts in global trade. The resilience medmix demonstrated in 2025 – supported by disciplined execution, operational excellence and a strong innovation pipeline – positions us well for the opportunities and challenges ahead. We are confident that we will further increase profitability and return to growth. Thank you for your attention and support.”

Chairman observations

René Willi hands back to the Chairman, who thanks him and adds that the company has successfully improved its profitability in recent years and that we are now focusing on driving revenue growth.

The Chairman also focuses on the cultural journey of the company, which is a prerequisite for the continuous and sustainable growth. An essential pillar of the company strategy is the transformation into an entrepreneurial, high-performing organization.

The Chairman notes that this year, the company made further progress by streamlining its structure and aligning business unit P&L ownership more closely with global functional responsibilities. A leaner organization was created, that enables faster, more direct decision-making and strengthens accountability across the business.

The Chairman also notes the strengthening of the management team through the appointment of Charity Kufas as Chief Strategy and Transformation Officer at the beginning of 2026, the appointment of Sven Luginbühl as new Group CFO and the appointment of Jennifer Dean who will take over leadership of the Beauty business unit.

The Chairman believes that the company is well on track with the implementation of its strategic priorities and is well positioned to capture future growth opportunities. Over the past year and a half, we have refined our strategy, improved our cost efficiency, and are now focusing much more strongly on high-margin applications and segments. This strategy is beginning to bear fruit. Operationally, today, we are in a more robust, focused, and solid position.

The Chairman notes that the Board of Directors proposes to adjust the dividend to CHF 0.10 per share for 2025. This reflects the company's capital allocation principles, which prioritize a strengthening of the balance sheet and investing in medmix' strategic initiatives. Going forward, medmix will adopt a performance-driven dividend policy, based on consolidated net income attributable to shareholders. A minimum of 40% of earnings per share will be distributed, with a higher payout ratio when performance and liquidity permit.

The Chairman closes his remarks by expressing his great appreciation and thanking shareholders, employees, customers and partners.

The Chairman announces that, at today's Annual General Meeting, 27,066,692 registered shares are represented, out of which 68,552 are represented by shareholders and 26,998,140 are represented by the independent proxy. This means that 65.6% of the registered share capital is represented today. Each registered share has a nominal value of CHF 0.01.

Agenda item 1: Annual report 2025

Agenda item 1.1: Business review, financial statements of medmix Ltd and consolidated financial statements 2025

The annual report, containing the business review, the financial statements and the consolidated financial statements, as well as the reports of the auditor are available on medmix' website.

The Chairman reiterates the key numbers from the income statement of the holding company, medmix Ltd, for the financial year 2025: The parent company's accounts show an income of CHF 28.1 million and expenses of CHF 14.5 million, resulting in a net profit of CHF 13.6 million.

The Chairman mentions that medmix' statutory financial statements have been prepared according to the accounting principles of the Swiss Code of Obligations.

The auditor's reports are included in the section "Financial Reporting" of the annual report, which is available for download on the company's website. The Chairman thanks KPMG AG for their work.

The Chairman states that the representative of KPMG AG, who is present, indicated, prior to the Annual General Meeting, that he has no additional comment to make on the reports.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the business review, the financial statements of medmix Ltd and the consolidated financial statements 2025 be approved.

The Chairman announces that the Annual General Meeting approved the business review, the financial statements of medmix Ltd and the consolidated financial statements 2025 with the following results:

Majority	13'533'347
Votes in favor	26'934'762
Votes against	46'348
Abstentions	85'582

Agenda item 1.2: Advisory vote on the compensation report 2025

The Chairman explains that agenda item 1.2 is a non-binding advisory vote.

The compensation report sets out the basic principles of medmix' compensation policy and plans, as well as the compensation of the members of the Board of Directors and the Executive Committee. The Chairman further explains the compensation policy of medmix for the Board of Directors and the Executive Committee.

The Chairman opens the discussion on this agenda item.

There is a request to speak from Mr. Guido Röthlisberger. Mr. Röthlisberger is displeased about the fact that the Board proposes a dividend of 0,10CHF for this year. He notes that the payments and boni to the management have not decreased at the same level as the share price and the dividend. Mr. Röthlisberger expects more transparency on management targets linked to incentives. He requests an explanation of why the dividend has been reduced to 0,10 CHF, while management bonuses are paid in full and what ratio is applied.

The Chairman thanks Mr. Röthlisberger for his question and expresses that he values General Meetings as they allow direct communication with the shareholders. He proposes to answer the question in different points.

First, as regards the dividend, the Board proposes a lower dividend to strengthen the balance sheet and ensure the capital needed to execute the strategy. The dividend policy is to go back to 40% or more allocation of dividends.

As regards the compensation, the short-term incentives of management are based on weighted KPIs such as Revenue, profitability and Cash, to ensure management focusses on keeping control over controllable items. Getting control over the profit and loss and balance sheet was key. For 2025, while the revenue target was not fully met, the other KPIs were exceeded, which led to a 100% payout.

The Chairman thanks Mr. Röthlisberger again for his comments and notes the importance of this exchange.

The Chairman asks whether there are further questions or comments.

As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the compensation report 2025, as included in the annual report 2025, be approved in a non-binding advisory vote.

The Chairman announces that the Annual General Meeting approved the compensation report 2025 in a non-binding advisory vote with the following results:

Majority	13'533'347
Votes in favor	19'998'332
Votes against	6'944'580
Abstentions	123'780

The Chairman thanks the shareholders for their approval and stresses that he and the board have heard the concern and understand that shareholders expect serious action from the board and management.

Agenda item 1.3: Sustainability report 2025

The sustainability report sets out in detail the non-financial governance and strategy-specific elements that supplement the information presented in other sections of the annual report 2025, describing medmix' people and culture focus, and addressing the approach, measures and progress against priorities and commitments on environmental matters, in particular CO₂ goals, social issues, employee-related issues, respect for human rights and medmix' efforts in combating corruption. The Chairman further refers to medmix' non-financial achievements and highlights.

The Chairman adds that the company achieved its 2025 greenhouse gas emissions targets and remains on track to achieve our SBTi-verified near term and long-term targets. The company broadened its offering of sustainable and post-consumer recycled material-based products, launching 15 new sustainable products in 2025 (matching its target), and closely monitored its operations and entire supply chain, and no cases of child or forced labour were identified, neither was the use of any conflict minerals or metals.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the sustainability report 2025, as included in the annual report 2025, be approved.

The Chairman announces that the Annual General Meeting approved the sustainability report 2025 with the following results:

Majority	13'533'347
Votes in favor	25'984'161
Votes against	1'008'945
Abstentions	73'586

Agenda item 2: Appropriation of annual result

The Board of Directors proposes to allocate the total balance of CHF 28'21'255, comprising the net profit for 2025 of CHF 13'570'776 and the retained profits of CHF 14'643'479, as follows: CHF 4'067'291 as ordinary dividend and CHF 24'146'965 as balance to be carried forward.

The Chairman explains that medmix pursues a dividend policy that takes into account the company's liquidity as well as its economic situation.

The proposal of the Board of Directors, before deduction of 35% Swiss withholding tax, will amount to CHF 0.10 per share, payable on 22 April 2026. All shares held by medmix Ltd and its subsidiaries on the record date are not entitled to dividends.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has approved the appropriation of the annual result proposed by the Board of Directors with the following results:

Majority	13'533'347
Votes in favor	26'892'694
Votes against	137'068
Abstentions	36'930

Agenda item 3: Discharge

The Board of Directors proposes that discharge be granted to the members of the Board of Directors and the Executive Committee for the financial year 2025.

The Chairman reminds the shareholders that, according to Art. 695 CO, the persons who were involved in the management of the company do not have the right to vote on the present agenda item. Furthermore, the Chairman states that Tiwel Holding AG voluntarily also accepted the same restriction for all shares held by it.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has granted discharge to the members of the Board of Directors and the Executive Committee with the following results:

Majority	5'116'579
Votes in favor	10'043'218
Votes against	109'117
Abstentions	80'822

The Chairman thanks the shareholders for the trust they have placed in the Board of Directors and the Executive Committee.

Agenda item 4: Compensation of the Board of Directors and the Executive Committee

The Chairman comes to the vote on the compensation of the Board of Directors and the Executive Committee. He mentions that agenda item 4 is divided into two sub-items with two separate votes: part 1, "Compensation of the Board of Directors", and part 2, "Compensation of the Executive Committee".

For detailed explanations on the approval of the submitted compensation, the Chairman refers to the separate report of the Board of Directors that the shareholders received with the invitation to this Annual General Meeting.

On the compensation of the Board of Directors, the Chairman states that the maximum total amount submitted for approval relates to the compensation for the term from today's Annual General Meeting to the Annual General Meeting 2027.

The proposed maximum total amount is CHF 1,500,000 and remains unchanged from last year. The members of the Board of Directors only receive fixed compensation to ensure their independence. They do not receive any variable or performance-related compensation, nor are they entitled to participate in medmix' pension plans. The compensation of the Board of Directors is partly paid in cash and partly in restricted stock units.

On the compensation of the Executive Committee, the Chairman states that the proposed maximum total amount relates to the compensation for the financial year 2027. The proposed amount of CHF 8,500,000, unchanged

compared to last year, covers the maximum total compensation of the members of the Executive Committee. The total compensation consists of a fixed base salary and a variable component. The variable component comprises a short-term performance-related bonus (in cash) and a long-term performance-related performance share unit plan. This system is designed to motivate above-average performance and to recognize this performance accordingly.

The Chairman mentions that this is a maximum amount. In accordance with legal requirements, the calculation of the maximum total amount of compensation for the Executive Committee takes into account the potential maximum amounts under the variable component of compensation, *i.e.*, both the short-term and long-term incentive systems.

The compensation actually paid out will be disclosed in the compensation report for the financial year 2027 which will be submitted to the shareholders for an advisory vote.

The Chairman opens the discussion on this agenda item.

Mr. Guido Rötisberger comes to the speaking desk. He would be interested to know the concrete targets that must be achieved by the executive management to receive the maximum bonus, or any bonus at all. He asks whether shareholders can verify these targets or whether they are only internal.

The Chairman states that transparency is important and that the Board will consider how to further enhance transparency on such a subject.

The Chairman thanks Mr. Rötisberger for his inputs and asks whether there are further requests to speak. As there are no further questions or comments, the Chairman proceeds to the vote.

Agenda item 4.1: Compensation of the Board of Directors

The Annual General Meeting votes on the approval of the total amount for the compensation of the Board of Directors for the term from the Annual General Meeting 2026 until the end of the Annual General Meeting 2027 in the maximum amount of CHF 1,500,000.

The Chairman notes that the Annual General Meeting approved the maximum total compensation of the Board of Directors for the term from the Annual General Meeting 2026 until the end of the Annual General Meeting 2027 with the following results:

Majority	13'533'347
Votes in favor	26'118'812
Votes against	859'471
Abstentions	88'409

Agenda item 4.2: Compensation of the Executive Committee

The Chairman continues with the vote on agenda item 4.2. The Annual General Meeting votes on the approval of the total amount for the compensation of the Executive Committee for the financial year 2027 in the maximum amount of CHF 8,500,000.

The Chairman notes that the Annual General Meeting has approved the maximum total compensation of the Executive Committee for the financial year 2027 with the following results:

Majority	13'533'347
Votes in favor	25'585'290
Votes against	1'374'585
Abstentions	106'817

Agenda item 5: Election of the Board of Directors

The Chairman mentions that agenda item 5 is divided into two sub-items with separate votes, namely agenda item 5.1 "Re-election of the Chairman of the Board of Directors" and agenda item 5.2 "Re-election of the other members of the Board of Directors".

Agenda item 5.1: Re-election of the Chairman of the Board of Directors

Marco Musetti takes over and states that the Board of Directors proposes that the shareholders re-elect Rob ten Hoedt as member and Chairman of the Board of Directors for a term until the end of the Annual General Meeting 2027.

Marco Musetti explains that Rob ten Hoedt has been elected as a member of the Board of Directors and as a member of the Nomination and Remuneration Committee at the Annual General Meeting 2022, while he was elected as Chairman of the Board of Directors at the Annual General Meeting 2023. Rob ten Hoedt was Executive Vice President & President, Europe, Middle East & Africa (EMEA) and Asia-Pacific (APAC) and a member of the Executive Committee of Medtronic until he retired from Medtronic in August 2024. For a detailed biography of Rob ten Hoedt, Marco Musetti refers shareholders to medmix' website.

Marco Musetti opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, Marco Musetti proceeds to the election.

Marco Musetti announces that the Annual General Meeting has re-elected Rob ten Hoedt as member and Chairman of the Board of Directors with the following results:

Majority	13'533'347
Votes in favor	24'274'645
Votes against	2'720'999
Abstentions	71'048

Marco Musetti congratulates the Chairman on his re-election and hands back to him.

Agenda item 5.2: Re-election of the other members of the Board of Directors

The Chairman states that all current members of the Board of Directors stand for re-election, and then introduces the members as follows:

Marco Musetti was elected as a member of the Board of Directors at the Annual General Meeting 2021. He has been vice-chairman of the Board of Directors since the Annual General Meeting 2021 and chairman of the Audit Committee since the Annual General Meeting 2022. He has been a member of the Board of Directors at several international companies and was also a member of the Board of Directors of Sulzer Ltd from 2011 to April 2021.

Barbara Angehrn was elected as a member of the Board of Directors at the Annual General Meeting 2022. She has also been a member of the Nomination and Remuneration Committee since the Annual General Meeting 2022. Barbara Angehrn has been Chief Executive Officer of Numab Therapeutics since September 2025.

Susanne Hundsbaek-Pedersen was elected as a member of the Board of Directors at the Annual General Meeting 2024. Since then, she has also been a member of the Audit Committee. Since January 2021, Susanne Hundsbaek-Pedersen has been Executive Vice President, Head of Global Technical Operations at F. Hoffmann-La Roche Ltd in Basel.

Daniel Flammer was elected as a member of the Board of Directors at the Annual General Meeting 2022. He has also been a member of the Audit Committee since then. Daniel Flammer has been Managing Partner of AR Financial Advisory AG in Zurich since April 2018.

David Metzger was elected as a member of the Board of Directors at the Annual General Meeting 2022. At the Annual General Meeting 2023, he was also elected as a member of the Nomination and Remuneration Committee. Since late 2025, David Metzger serves as Investment and Portfolio Manager at A2 Link.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Chairman starts with the re-election of Marco Musetti under agenda item 5.2.1. The Board of Directors proposes to re-elect Marco Musetti as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Marco Musetti to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	20'948'451
Votes against	6'050'090
Abstentions	68'151

The Chairman continues with the re-election of Barbara Angehrn under agenda item 5.2.2. The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	26'599'179
Votes against	383'415
Abstentions	84'098

The Chairman continues with the re-election of Susanne Hundsbaek-Pedersen under agenda item 5.2.3. The Board of Directors proposes to re-elect Susanne Hundsbaek-Pedersen as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Susanne Hundsbaek-Pedersen to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	26'889'577
Votes against	109'341
Abstentions	67'774

The Chairman continues with the re-election of Daniel Flammer under agenda item 5.2.4. The Board of Directors proposes to re-elect Daniel Flammer as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Daniel Flammer to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	21'792'745
Votes against	5'205'283
Abstentions	68'664

The Chairman continues with the re-election of David Metzger under agenda item 5.2.5. The Board of Directors proposes to re-elect David Metzger as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	25'125'673
Votes against	1'867'051
Abstentions	73'968

Agenda item 6: Re-election of the Nomination & Remuneration Committee

The Chairman states that the Board of Directors proposes that shareholders re-elect Barbara Angehrn, Rob ten Hoedt and David Metzger as members of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting. Barbara Angehrn and Rob ten Hoedt joined the Nomination & Remuneration Committee in 2022, while David Metzger was elected as a member at the Annual General Meeting 2023.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	25'524'547
Votes against	1'450'700
Abstentions	91'445

The Chairman hands over to Marco Musetti who continues with the re-election of Rob ten Hoedt under agenda item 6.2. The Board of Directors proposes to re-elect Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

Marco Musetti notes that the Annual General Meeting has re-elected Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	22'663'749
Votes against	4'325'705
Abstentions	77'238

Marco Musetti hands back over to the Chairman who continues with the re-election of David Metzger under agenda item 6.3. The Board of Directors proposes to re-elect David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	13'533'347
Votes in favor	23'616'012
Votes against	3'372'371
Abstentions	78'309

Agenda item 7: Re-election of the Auditor

The Chairman continues with the re-election of the auditor.

The Board of Directors proposes to re-elect KPMG as auditor for the financial year 2026.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected KPMG as auditor with the following results:

Majority	13'533'272
Votes in favor	26'897'060
Votes against	98'164
Abstentions	71'318

Agenda item 8: Re-election of the Independent Proxy

The Chairman continues with the re-election of the independent proxy under agenda item 8.

The Board of Directors proposes to re-elect Proxy Voting Services GmbH for a term until the end of the next Annual General Meeting as the independent proxy. Proxy Voting Services GmbH fulfils the requirements of independence, in particular because it is not connected to medmix through any other activities.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected Proxy Voting Services GmbH, for a term until the end of the next Annual General Meeting as independent proxy with the following results:

Majority	13'533'272
Votes in favor	26'967'718
Votes against	31'676
Abstentions	67'148

As there are no further questions or comments, the Chairman closes this year's Annual General Meeting. He thanks shareholders for their interest and continued trust in medmix. He invites shareholders to a reception on the premises.

Closing of the meeting: 11:30 a.m.

The Chairman:

The Secretary:

[SIGNATURE]

[SIGNATURE]¹

Rob ten Hoedt

Xavier Schops

¹ Original versions, signed by the Chairman and Secretary are maintained at the registered office.